Tag Archives: DNA

Dolly Led to Slaughter – Part II

Posted on May 9, 2014 by Warren Woessner

As I read and re-read In re Roslin, App. No.  2013-1407 (Fed. Cir., May 8, 2014), before going across the street to “testify” at the PTO 101 Forum, I was struck by how the logical pathway chosen by the panel … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | Leave a comment

Sanofi-Aventis v. Pfizer – Possession and Appreciation Trump Structure

Posted on November 6, 2013 by Warren Woessner

On Tuesday, the Fed. Cir. affirmed a finding by the Board that Pfizer was entitled to an earlier priority date for a claim to  cDNA encoding the IL-13 receptor protein (Sanofi-Aventis v. Pfizer, Inc., App. No. 2012-1345 (Fed. Cir. November … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , | Leave a comment

Complimentary Webinar: Patenting DNA

Posted on July 25, 2013 by Warren Woessner

Join Robin Chadwick and me as we untangle the web of rulings in the upcoming webinar “Patenting DNA: Why DNA is Different and What to Do About It.”  The live CLE webinar will be presented on Wednesday, August 7th at … Continue reading →

Posted in Patent Eligible Subject Matter, Webinar | Tagged , , , , , , | Leave a comment

Association For Molecular Pathology V Myriad Genetics – An Isolated Local Difficulty?

Posted on June 14, 2013 by Warren Woessner

Paul Cole, Professor of Intellectual Property Law at Bournemouth University and European Patent Attorney at Lucas & Co, Warlingham, Surrey, UK discusses yesterdays Myriad ruling by the Supreme Court. How does yesterday’s Supreme Court decision match international opinion on the patentability … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment